The Chinese authorities have granted a marketing authorisation for Pierre Fabre Laboratories’ Braftovi, in combination with cetuximab, for the treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer, after prior systemic therapy. The approval is based on the Phase III BEACON CRC trial, which demonstrated a significant improvement in overall survival of patients treated with […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!